Severity
Low
FDA Drug recall · Reported November 5, 2014
Labeling: Incorrect or Missing Package Insert
Valeant Pharmaceuticals North America LLC recalled APLENZIN¿ (bupropion hydrobromide), extended-release tablets, 174 mg, 7-count HDPE bottle… - a low-severity action.
APLENZIN¿ (bupropion hydrobromide), extended-release tablets, 174 mg, 7-count HDPE bottle… was recalled by Valeant Pharmaceuticals North America LLC in November 5, 2014. Reason: Labeling: Incorrect or Missing Package Insert. Check the official notice for the remedy. Verify recall #D-0051-2015 with the FDA Drug before acting.
The recall
Valeant Pharmaceuticals North America LLC issued this low-severity FDA Drug recall-Labeling: Incorrect or Missing Package Insert.
Sourced from official FDA Drug enforcement records. Verify recall #D-0051-2015 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0051-2015) was formally reported on November 5, 2014, with the manufacturer initiating the action on June 5, 2014. It is classified under Low severity (Class III), with a current status of Terminated. Valeant Pharmaceuticals North America LLC is listed as the recalling firm, operating out of Bridgewater, NJ. Federal records list the affected scope as 20,499 HDPE bottles.
The documented reason for this recall is: Labeling: Incorrect or Missing Package Insert Distribution data in the federal record shows the product reached: Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,731 children & baby products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
20,499 HDPE bottles
Related Recalls
6
0 from same agency
APLENZIN¿ (bupropion hydrobromide), extended-release tablets, 174 mg, 7-count HDPE bottle, Rx Only, Manufactured by Valeant Pharmaceuticals International, Inc. Steinbach MB, Canada R5G 1Z7, NDC 0024-5810-07.
Labeling: Incorrect or Missing Package Insert
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0051-2015 |
| Date reported | November 5, 2014 |
| Date initiated | June 5, 2014 |
| Recalling firm | Valeant Pharmaceuticals North America LLC |
| Firm location | Bridgewater, NJ |
| Affected scope | 20,499 HDPE bottles |
| Distribution | Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Xishentang Dongguan Trading Co, Ltd., dba Pretty-Life, of China · 2026-07-02
Diamond Wipes International, Inc. of Chino, California · 2026-07-02
· 2026-07-02
· 2026-07-02
Sanven Technology Ltd., dba Vevor, of Rancho Cucamonga, California · 2026-07-02
Compare this recall with AMASKY Nursing Pillows Recalled Due to Risk of Serious Inju… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 5, 2014. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.